Article

The role of osteocyte apoptosis in cancer chemotherapy-induced bone loss

Sansom Institute for Health Research, School of Pharmacy and Medical Sciences, Division of Health Sciences, University of South Australia, Adelaide, Australia.
Journal of Cellular Physiology (Impact Factor: 3.87). 07/2012; 227(7):2889-97. DOI: 10.1002/jcp.23034
Source: PubMed

ABSTRACT Intensive cancer chemotherapy leads to significant bone loss, the underlying mechanism of which remains unclear. The objective of this study was to elucidate mechanisms for effect of the commonly used anti-metabolite methotrexate (MTX) on osteocytes and on general bone homeostasis. The current study in juvenile rats showed that MTX chemotherapy caused a 4.3-fold increase in the number of apoptotic osteocytes in tibial metaphysis, which was accompanied by a 1.8-fold increase in the number of tartrate-resistant acid phosphatase-positive bone resorbing osteoclasts, and a 35% loss of trabecular bone. This was associated with an increase in transcription of the osteoclastogenic cytokines IL-6 (10-fold) and IL-11 (2-fold). Moreover, the metaphyseal bone of MTX-treated animals exhibited a 37.6% increase in the total number of osteocytes, along with 4.9-fold higher expression of the DMP-1 transcript. In cultured osteocyte-like MLO-Y4 cells, MTX treatment significantly increased caspase-3-mediated apoptosis, which was accompanied by the formation of plasma membrane-born apoptotic bodies and an increase in IL-6 (24-fold) and IL-11 (29-fold) mRNA expression. Conditioned media derived from MTX-treated MLO-Y4 cells was twice as strong as untreated media in its capacity to induce osteoclast formation in primary bone marrow osteoclast precursors. Thus, our in vivo and in vitro data suggested that MTX-induced apoptosis of osteocytes caused higher recruitment of DMP-1 positive osteocytes and increased osteoclast formation, which could contribute towards the loss of bone homeostasis in vivo.

Full-text

Available from: Cory Xian, May 02, 2014
2 Followers
 · 
181 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We describe here an ultrasensitive and fast protocol called a GEMO Assay (Genomodifier capacity assay). This non-cell method was developed to identify chemicals with genomodifier (genotoxic and/or genoprotective) capacity. The assay is performed in a black 96-well plate using calf thymus dsDNA exposed to different concentrations of chemicals tested (CT) for 30 minutes with and without the addition of a pro-oxidant substance that causes dsDNA damage (H2O2, 3M). Furthermore, PicoGreen®, a highly sensitive dsDNA dye is added and the dsDNA fluorescence. Chemicals that cause a break in dsDNA are identified by a decrease in fluorescence in comparison with the fluorescence observed in an untreated dsDNA (control group) indicating a genotoxic capacity. On the contrary, attenuation of dsDNA degradation caused by H2O2 exposition indicates CT genoprotective capacity. The GEMO Assay was validated by comparing peripheral blood mononuclear cells (PBMCs) and an HT29 colorectal cell line exposed to similar conditions where the effect on dsDNA was also evaluated by a DNA Alkaline Comet Assay. Vitamin C was used as CT and other variables were also evaluated to confirm the cytotoxic action of H2O2. The results showed a strong negative correlation between the GEMO Assay and the Comet Assay performed in PBMCs (r2 = -0.828; p<0.0001) since higher dsDNA fluorescence measured by the GEMO Assay was associated with lower index damage measured by the DNA Alkaline Comet Assay. Therefore, the GEMO Assay could be useful to early screening of genoprotective and genotoxic effects of chemicals and plant extracts without interfering cell biological variables.
    Analytical methods 08/2014; 6(21). DOI:10.1039/C4AY01709A · 1.94 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The portrait of osteoblasts and osteocytes has been subjected to a revision, since a large body of evidence are attributing these cells amazing roles both inside and outside the bone. The osteoblast, long confined to its bone building function, is actually a very eclectic cell, actively regulating osteoclast formation and function as well as hematopoietic stem cells homeostasis. It is also an endocrine cell, affecting energy metabolism, male fertility and cognition through the release of osteocalcin, a perfect definition-fitting hormone in its uncarboxylated state. As for the osteocytes, many evidence shows that they do not merely represent the final destination of the osteoblasts, but they are instead very active cells that, besides a mechanosensorial function, actively contribute to the bone remodelling by regulating bone formation and resorption. The regulation is exerted by the production of Sclerostin (SOST), which in turn inhibits osteoblast differentiation by blocking Wnt/beta-catenin pathway. At the same time, osteocytes influence bone resorption both indirectly, by producing RANKL, which stimulates osteoclastogenesis, and directly by means of a local osteolysis, which is observed especially under pathological conditions. The great versatility of both these cells reflects the complexity of the bone tissue, which has not only a structural role, but influences and is influenced by different organs, taking part in homeostatic and adaptive responses affecting the whole organism.
    Archives of Biochemistry and Biophysics 05/2014; DOI:10.1016/j.abb.2014.05.003 · 3.04 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Methotrexate (MTX) is a folic acid antagonist used in high doses as an anti-cancer treatment and in low doses for the treatment of some autoimmune diseases. MTX use has been linked to oxidative imbalance, which may cause multi-organ toxicities that can be attenuated by antioxidant supplementation. Despite the oxidative effect of MTX, the influence of antioxidant gene polymorphisms on MTX toxicity is not well studied. Therefore, we analyzed here whether a genetic imbalance of the manganese-dependent superoxide dismutase (SOD2) gene could have some impact on the MTX cytotoxic response. An in vitro study using human peripheral blood mononuclear cells (PBMCs) obtained from carriers with different Ala16Val-SOD2 genotypes (AA, VV and AV) was carried out, and the effect on cell viability and proliferation was analyzed, as well as the effect on oxidative, inflammatory and apoptotic markers. AA-PBMCs that present higher SOD2 efficiencies were more resistance to high MTX doses (10 and 100 µM) than were the VV and AV genotypes. Both lipoperoxidation and ROS levels increased significantly in PBMCs exposed to MTX independent of Ala16Val-SOD2 genotypes, whereas increased protein carbonylation was observed only in PBMCs from V allele carriers. The AA-PBMCs exposed to MTX showed decreasing SOD2 activity, but a concomitant up regulation of the SOD2 gene was observed. A significant increase in glutathione peroxidase (GPX) levels was observed in all PBMCs exposed to MTX. However, this effect was more intense in AA-PBMCs. Caspase-8 and -3 levels were increased in cells exposed to MTX, but the modulation of these genes, as well as that of the Bax and Bcl-2 genes involved in the apoptosis pathway, presented a modulation that was dependent on the SOD2 genotype. MTX at a concentration of 10 µM also increased inflammatory cytokines (IL-1β, IL-6, TNFα and Igγ) and decreased the level of IL-10 anti-inflammatory cytokine, independent of SOD2 genetic background. The results suggest that potential pharmacogenetic effect on the cytotoxic response to MTX due differential redox status of cells carriers different SOD2 genotypes.
    PLoS ONE 10/2014; 9(10):e107299. DOI:10.1371/journal.pone.0107299 · 3.53 Impact Factor